Levetiracetam Bluefish (Levetiracetam)

Levetiracetam exerts its effect by binding to the synaptic vesicle protein SV2A in the brain. This binding modulates neurotransmitter release, stabilizing neuronal firing and decreasing excessive excitatory activity that can trigger seizures. The result is a lowered propensity for seizure generation across various epilepsy types.

The appropriate dose of Levetiracetam Bluefish is individualized by the prescribing healthcare professional based on the patient’s age, weight, renal function, and seizure type. Dosage adjustments are made to achieve optimal seizure control while minimizing side effects, and the prescriber determines the exact regimen.

Safety data for levetiracetam in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their healthcare provider before initiating or continuing therapy.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levetiracetam offers a distinct mechanism by targeting SV2A, which differs from sodium‑channel blockers like carbamazepine or GABA‑enhancers such as valproate. It generally has fewer drug‑enzyme interactions, a favorable tolerability profile, and does not require routine therapeutic drug monitoring, making it a convenient option for many patients.

Store the product at ambient temperature, preferably below 25 °C. Keep the tablets in their original packaging to protect them from moisture and light. Do not store in a refrigerator or freezer, and keep out of reach of children.

Levetiracetam Bluefish is taken orally, usually with or without food. Tablets should be swallowed whole with a full glass of water. The exact timing and frequency are determined by the prescriber, who may advise dosing once or twice daily based on clinical response.

Serious adverse events include severe psychiatric reactions such as depression, suicidal ideation, or aggression, as well as hypersensitivity reactions like rash, hives, or angioedema. Rare hematologic abnormalities such as neutropenia or thrombocytopenia have also been reported. Prompt medical attention is required if any of these occur.

Patients with a known hypersensitivity to levetiracetam or any of the product’s excipients should avoid its use. Caution is advised in individuals with severe renal impairment, as dose adjustment may be required, and in those with a history of serious psychiatric disorders.